From GlobeNewswire: 2025-01-20 19:00:00

Disc Medicine, Inc. will host a conference call to discuss feedback received from its Type C meeting on bitopertin in EPP with the FDA. Bitopertin is a potential treatment for hematologic diseases like erythropoietic porphyrias, where it may be the first disease-modifying therapy. Erythropoietic Protoporphyria (EPP) is a rare, debilitating disease caused by mutations affecting heme biosynthesis. Patients experience severe reactions to sunlight, impacting their quality of life. Disc Medicine is dedicated to developing treatments for serious hematologic diseases. For more information, visit their website.



Read more at GlobeNewswire: Disc Medicine to Host Conference Call on Type C Meeting for